
Please try another search
On Monday, shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , a company that focuses on the discovery and development of RNA-based therapeutics, are surging, up over 12% after research firm Oppenheimer upgraded its stock after they cited several supporting factors for eterplirsen’s accelerated approval.
Analyst Christopher Marai upgraded SRPT to ‘Outperform’ from ‘Perform’ while keeping the price target of $60.
Enterplirsen isdesigned for the treatment of some mutations that cause Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease. An FDA advisory committee believes patients suffering from the disease will likely see improvement with the use of eterplirsen.
Recent FDA decisions have created some flexibility to address unmet needs, while encouraging drug development. Oppenheimer also noted that "the FDA takes into consideration more than just science law. They gave an example of the approval of Addyi for the treatment of female patients with sexual dysfunction, and despite the drug having only marginal efficacy, it was approved because of unmet needs, patient advocacy, and desired incentivized drug development."
The markets have been sluggish this week as investors hope for a jolt later in the week when AI juggernaut NVIDIA Corporation (NASDAQ:NVDA) reports fourth quarter and year-end...
On Friday, a wave of selling pressure swept across the US equity markets, leaving a trail of losses. The S&P 500 closed down 1.7%, the DOW slid 1.69%, and the NASDAQ tumbled a...
Palantir remains highly valued with a 460x P/E ratio and a 42.5x P/B ratio, far above its peers. The stock's beta of 2.81 signals high volatility, meaning sharp moves in both...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.